Foghorn Therapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Deerfield Management and associated entities have filed a Schedule 13G reporting an 8.64% beneficial ownership stake in Foghorn Therapeutics Inc.
NASDAQ
FMR LLC and Abigail P. Johnson report beneficial ownership of 11.6% of Foghorn Therapeutics Inc. common stock as of March 31, 2026.
NASDAQ
SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant 10.2% Stake in Foghorn Therapeutics
FMR LLC and Abigail P. Johnson have reported a continued beneficial ownership of 10.2% of Foghorn Therapeutics Inc.'s common stock as of December 31, 2024, through a Schedule 13G Amendment No. 5 filing.